Liquidia Corporation Stock Price Potential Analysis
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy LQDA?
Source: NASDAQ.COM
- Price Target Analysis: Liquidia Corporation's average price target of $50.67 indicates a 34.5% upside from the current price of $37.68, although the lowest target of $19.00 suggests a 49.6% downside risk, reflecting significant divergence among analysts.
- Earnings Outlook Upgrade: Analysts have shown increasing optimism regarding Liquidia's earnings prospects, with the Zacks Consensus Estimate rising by 67.1% over the past month, as three estimates increased while one decreased, indicating enhanced market confidence in the company's future performance.
- Analyst Rating: Liquidia currently holds a Zacks Rank of #2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on four earnings estimate-related factors, further supporting its potential for stock price appreciation.
- Caution for Investors: While analysts' price targets provide some guidance, investors should approach these targets with skepticism, as historical data shows that analysts often set overly optimistic targets, which can lead to poor investment decisions.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LQDA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LQDA
Wall Street analysts forecast LQDA stock price to rise
8 Analyst Rating
8 Buy
0 Hold
0 Sell
Strong Buy
Current: 37.470
Low
31.00
Averages
47.50
High
67.00
Current: 37.470
Low
31.00
Averages
47.50
High
67.00
About LQDA
Liquidia Corporation is a biopharmaceutical company. The Company is focused on the development, manufacture and commercialization of products that address unmet patient needs, with a focus directed towards rare cardiopulmonary diseases, such as pulmonaryarterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The Company operate through its wholly owned operating subsidiaries, Liquidia Technologies, Inc. and Liquidia PAH, LLC. Its proprietary PRINT technology is a particle engineering platform, which enable precise production of uniform drug particles. Its lead product candidate is YUTREPIA for the treatment of PAH and PH-ILD. YUTREPIA is an inhaled dry powder formulation of treprostinil designed with PRINT to improve the therapeutic profile of treprostinil by enhancing deep lung delivery while using a convenient, dry-powder inhaler (DPI) and by achieving higher dose levels than the labeled doses of current inhaled therapies.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Liquidia Corporation Stock Price Potential Analysis
- Price Target Analysis: Liquidia Corporation's average price target of $50.67 indicates a 34.5% upside from the current price of $37.68, although the lowest target of $19.00 suggests a 49.6% downside risk, reflecting significant divergence among analysts.
- Earnings Outlook Upgrade: Analysts have shown increasing optimism regarding Liquidia's earnings prospects, with the Zacks Consensus Estimate rising by 67.1% over the past month, as three estimates increased while one decreased, indicating enhanced market confidence in the company's future performance.
- Analyst Rating: Liquidia currently holds a Zacks Rank of #2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on four earnings estimate-related factors, further supporting its potential for stock price appreciation.
- Caution for Investors: While analysts' price targets provide some guidance, investors should approach these targets with skepticism, as historical data shows that analysts often set overly optimistic targets, which can lead to poor investment decisions.
See More
Liquidia Executive Sells 80,000 Shares of Stock
- Executive Stock Sale: Liquidia's Chief Commercial Officer Scott Moomaw reported the sale of 80,000 shares of common stock, valued at approximately $2.8 million, as per SEC Form 4, indicating a strategic liquidity management approach.
- Transaction Context: This sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted in November 2025, reflecting a significant increase compared to Moomaw's average sell transaction of 4,848.5 shares since January 2025, highlighting a major impact on his remaining holdings.
- Shareholding Changes: Post-transaction, Moomaw's direct stock holdings decreased by 29.74% to 188,954 shares, while he retains 25,300 outstanding stock options, demonstrating continued alignment with shareholder interests.
- Market Performance: Liquidia shares were priced at $35.32 on March 9, 2026, with a one-year total return of 159.4%, and although Moomaw's sale may negatively affect market sentiment, he still holds approximately $6.8 million in equity, indicating confidence in the company's future.
See More
Liquidia Executive Sells 80,000 Shares of Stock
- Executive Share Reduction: Liquidia's Chief Commercial Officer Scott Moomaw sold 80,000 shares of common stock on March 9, 2026, for approximately $2.83 million, representing a 29.74% reduction in his direct holdings, now totaling 188,954 shares, indicating a cautious outlook on the company's future.
- Equity Structure Change: The transaction involved exercising options and immediately selling the shares, while Moomaw retains 25,300 incentive stock options, suggesting he still has potential ownership despite the reduction in direct holdings.
- Performance Improvement: Liquidia recorded an operating profit of $19.8 million in Q4 2025, a significant turnaround from a $36.1 million operating loss in the same period last year, highlighting the company's potential and market demand for new therapies.
- Sales Growth: Yutrepia, an inhalable form of treprostinil launched in June 2025, achieved sales of $90.1 million in Q4, demonstrating Liquidia's competitive edge and innovative capabilities in the pulmonary arterial hypertension treatment market.
See More
Liquidia Executive Sells 80,000 Shares for $2.8M
- Significant Sale Size: Liquidia's Chief Commercial Officer Scott Moomaw sold 80,000 shares of common stock for approximately $2.8 million, which is substantially larger than his average transaction of 4,848.5 shares since January 2025, indicating a notable shift in his remaining capacity.
- Transaction Structure and Rationale: The sale was executed as an option exercise with immediate sale under a pre-arranged Rule 10b5-1 trading plan adopted in November 2025, aligning with routine liquidity management strategies, reflecting Moomaw's cautious approach to managing his holdings.
- Impact on Holdings: Moomaw's direct common stock holdings decreased by 29.74% to 188,954 shares; however, he retains 25,300 outstanding stock options that could be exercised for additional shares, supporting continued alignment with shareholder interests.
- Market Context Analysis: The transaction occurred with Liquidia shares priced around $35.32, following a 159.4% one-year total return, leaving Moomaw with a post-sale equity position valued at approximately $6.8 million, suggesting that while the sale may raise market concerns, it does not indicate a pessimistic outlook on the company's future.
See More
Novartis Proposes Acquisition of Excellergy to Expand Immunology Pipeline
- Acquisition Scale: Novartis has announced a proposed acquisition of Excellergy for up to $2 billion, including upfront and milestone payments, expected to close in the second half of 2026, demonstrating the company's strategic commitment to expanding its immunology pipeline.
- Therapeutic Potential: Exl-111, a next-generation anti-IgE antibody currently in phase I trials, could significantly broaden Novartis' market reach across high-value indications such as food allergies and chronic urticaria if clinical data validate early findings.
- Enhanced Allergy Portfolio: This acquisition complements Novartis' existing allergy product line, particularly the co-promoted Xolair with Roche, further solidifying its deep expertise in IgE biology and supporting long-term growth in the immunology sector.
- Market Performance and Outlook: Novartis shares have risen 33% over the past year, significantly outperforming the industry growth of 10.1%, and despite facing generic competition for key drugs, the company is banking on key growth drivers like Kisqali and Kesimpta to support revenue growth.
See More
Liquidia Executive Sells Shares to Lock in Gains Amid Strong Performance
- Executive Share Sale: Liquidia's Chief Medical Officer Rajeev Saggar sold 35,365 shares on March 13, 2026, for approximately $1.28 million, indicating confidence in the company's future while also reflecting a profit-taking strategy amid rising stock prices.
- Ownership Stake Change: This transaction reduced Saggar's direct holdings from 209,838 to 174,473 shares, with a direct ownership value of about $6.4 million, suggesting he maintains a positive outlook on Liquidia's long-term prospects.
- Sale Size Comparison: The number of shares sold is significantly larger than Saggar's recent average sale of 6,462 shares, representing 16.85% of his direct holdings compared to a recent median of 1.97%, demonstrating his keen awareness of market dynamics.
- Company Financial Performance: Liquidia achieved $148.3 million in product sales in 2025, primarily driven by the successful launch of YUTREPIA, although the company reported a full-year net loss of approximately $68.9 million; however, a strong cash position of about $190.7 million provides a buffer for future growth.
See More
Liquidia Corporation Stock Price Potential Analysis
- Price Target Analysis: Liquidia Corporation's average price target of $50.67 indicates a 34.5% upside from the current price of $37.68, although the lowest target of $19.00 suggests a 49.6% downside risk, reflecting significant divergence among analysts.
- Earnings Outlook Upgrade: Analysts have shown increasing optimism regarding Liquidia's earnings prospects, with the Zacks Consensus Estimate rising by 67.1% over the past month, as three estimates increased while one decreased, indicating enhanced market confidence in the company's future performance.
- Analyst Rating: Liquidia currently holds a Zacks Rank of #2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on four earnings estimate-related factors, further supporting its potential for stock price appreciation.
- Caution for Investors: While analysts' price targets provide some guidance, investors should approach these targets with skepticism, as historical data shows that analysts often set overly optimistic targets, which can lead to poor investment decisions.
See More
Liquidia Executive Sells 80,000 Shares of Stock
- Executive Stock Sale: Liquidia's Chief Commercial Officer Scott Moomaw reported the sale of 80,000 shares of common stock, valued at approximately $2.8 million, as per SEC Form 4, indicating a strategic liquidity management approach.
- Transaction Context: This sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted in November 2025, reflecting a significant increase compared to Moomaw's average sell transaction of 4,848.5 shares since January 2025, highlighting a major impact on his remaining holdings.
- Shareholding Changes: Post-transaction, Moomaw's direct stock holdings decreased by 29.74% to 188,954 shares, while he retains 25,300 outstanding stock options, demonstrating continued alignment with shareholder interests.
- Market Performance: Liquidia shares were priced at $35.32 on March 9, 2026, with a one-year total return of 159.4%, and although Moomaw's sale may negatively affect market sentiment, he still holds approximately $6.8 million in equity, indicating confidence in the company's future.
See More
Liquidia Executive Sells 80,000 Shares of Stock
- Executive Share Reduction: Liquidia's Chief Commercial Officer Scott Moomaw sold 80,000 shares of common stock on March 9, 2026, for approximately $2.83 million, representing a 29.74% reduction in his direct holdings, now totaling 188,954 shares, indicating a cautious outlook on the company's future.
- Equity Structure Change: The transaction involved exercising options and immediately selling the shares, while Moomaw retains 25,300 incentive stock options, suggesting he still has potential ownership despite the reduction in direct holdings.
- Performance Improvement: Liquidia recorded an operating profit of $19.8 million in Q4 2025, a significant turnaround from a $36.1 million operating loss in the same period last year, highlighting the company's potential and market demand for new therapies.
- Sales Growth: Yutrepia, an inhalable form of treprostinil launched in June 2025, achieved sales of $90.1 million in Q4, demonstrating Liquidia's competitive edge and innovative capabilities in the pulmonary arterial hypertension treatment market.
See More
Liquidia Executive Sells 80,000 Shares for $2.8M
- Significant Sale Size: Liquidia's Chief Commercial Officer Scott Moomaw sold 80,000 shares of common stock for approximately $2.8 million, which is substantially larger than his average transaction of 4,848.5 shares since January 2025, indicating a notable shift in his remaining capacity.
- Transaction Structure and Rationale: The sale was executed as an option exercise with immediate sale under a pre-arranged Rule 10b5-1 trading plan adopted in November 2025, aligning with routine liquidity management strategies, reflecting Moomaw's cautious approach to managing his holdings.
- Impact on Holdings: Moomaw's direct common stock holdings decreased by 29.74% to 188,954 shares; however, he retains 25,300 outstanding stock options that could be exercised for additional shares, supporting continued alignment with shareholder interests.
- Market Context Analysis: The transaction occurred with Liquidia shares priced around $35.32, following a 159.4% one-year total return, leaving Moomaw with a post-sale equity position valued at approximately $6.8 million, suggesting that while the sale may raise market concerns, it does not indicate a pessimistic outlook on the company's future.
See More
Novartis Proposes Acquisition of Excellergy to Expand Immunology Pipeline
- Acquisition Scale: Novartis has announced a proposed acquisition of Excellergy for up to $2 billion, including upfront and milestone payments, expected to close in the second half of 2026, demonstrating the company's strategic commitment to expanding its immunology pipeline.
- Therapeutic Potential: Exl-111, a next-generation anti-IgE antibody currently in phase I trials, could significantly broaden Novartis' market reach across high-value indications such as food allergies and chronic urticaria if clinical data validate early findings.
- Enhanced Allergy Portfolio: This acquisition complements Novartis' existing allergy product line, particularly the co-promoted Xolair with Roche, further solidifying its deep expertise in IgE biology and supporting long-term growth in the immunology sector.
- Market Performance and Outlook: Novartis shares have risen 33% over the past year, significantly outperforming the industry growth of 10.1%, and despite facing generic competition for key drugs, the company is banking on key growth drivers like Kisqali and Kesimpta to support revenue growth.
See More
Liquidia Executive Sells Shares to Lock in Gains Amid Strong Performance
- Executive Share Sale: Liquidia's Chief Medical Officer Rajeev Saggar sold 35,365 shares on March 13, 2026, for approximately $1.28 million, indicating confidence in the company's future while also reflecting a profit-taking strategy amid rising stock prices.
- Ownership Stake Change: This transaction reduced Saggar's direct holdings from 209,838 to 174,473 shares, with a direct ownership value of about $6.4 million, suggesting he maintains a positive outlook on Liquidia's long-term prospects.
- Sale Size Comparison: The number of shares sold is significantly larger than Saggar's recent average sale of 6,462 shares, representing 16.85% of his direct holdings compared to a recent median of 1.97%, demonstrating his keen awareness of market dynamics.
- Company Financial Performance: Liquidia achieved $148.3 million in product sales in 2025, primarily driven by the successful launch of YUTREPIA, although the company reported a full-year net loss of approximately $68.9 million; however, a strong cash position of about $190.7 million provides a buffer for future growth.
See More
